Current and Future Strategies for Relapsed Neuroblastoma: Challenges on the Road to Precision Therapy

@article{Morgenstern2013CurrentAF,
  title={Current and Future Strategies for Relapsed Neuroblastoma: Challenges on the Road to Precision Therapy},
  author={D. Morgenstern and S. Baruchel and M. Irwin},
  journal={Journal of Pediatric Hematology/Oncology},
  year={2013},
  volume={35},
  pages={337–347}
}
  • D. Morgenstern, S. Baruchel, M. Irwin
  • Published 2013
  • Medicine
  • Journal of Pediatric Hematology/Oncology
  • More than half of the patients with high-risk neuroblastoma (NB) will relapse despite intensive multimodal therapy, with an additional 10% to 20% refractory to induction chemotherapy. Management of these patients is challenging, given disease heterogeneity, resistance, and organ toxicity including poor hematological reserve. This review will discuss the current treatment options and consider novel therapies on the horizon. Cytotoxic chemotherapy regimens for relapse and refractory NB typically… CONTINUE READING
    65 Citations
    Cancer stem cells in neuroblastoma therapy resistance
    • 8
    • PDF
    Oxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk Neuroblastoma
    • 7
    Neuroblastoma: paradigm for precision medicine.
    • 155
    • PDF
    Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside
    • 6

    References

    SHOWING 1-10 OF 151 REFERENCES
    New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome
    • 60
    • PDF
    Neuroblastoma: Therapeutic strategies for a clinical enigma.
    • 154
    • PDF
    Disialoganglioside Directed Immunotherapy of Neuroblastoma
    • 108
    Promising Therapeutic Targets in Neuroblastoma
    • 142
    • PDF
    New therapeutic targets for the treatment of high‐risk neuroblastoma
    • 93
    Targeting ALK in neuroblastoma—preclinical and clinical advancements
    • 116